Sanofi Shares Rise 0.92% at Close, Attempting to Exit Weak Zone
Sanofi shares ended the trading session on Tuesday, December 30, with a gain of 0.92%, closing at 83 euros after finishing at 82.24 euros the previous day. However, trading volumes remained limited, with only 0.11% of the capital traded. The stock continues a technical recovery over seven days, showing a weekly gain of 1.74% and a quarterly rise of 6.03%, despite an annual decline of 11.02% reflecting the challenging year faced by the pharmaceutical company.
Technical Indicators and Market Position
Sanofi's share price at 83 euros remains under pressure from moving averages, signaling an unfavorable underlying trend. The 50-day moving average at 85.56 euros and the 200-day moving average at 86.62 euros represent resistance levels to overcome to confirm a sustainable turnaround. The RSI at 47 indicates a neutral position, without extremes, leaving the stock in a zone of technical indecision. The support threshold at 80.60 euros is a key floor to maintain in upcoming sessions, while the resistance at 89.89 euros appears as the immediate target if the rebound continues. The MACD indicator shows a positive histogram at 0.12, indicating the beginning of an improvement in bullish momentum, although the MACD line remains negative at -1.06. This early technical signal suggests an attempt at stabilization after several weeks of consolidation. The monthly volatility of 5.09% remains contained, reflecting a relative calm in the stock, conducive to a measured progression.
Strategic Moves and Analyst Perspectives
The announcement on December 24 of the acquisition of Dynavax Technologies for $2.2 billion marked Sanofi's aggressive strategy in the adult vaccine market. This deal, including the HEPLISAV-B vaccine against hepatitis B, strengthens the group's portfolio in a high-potential segment. The agreement with the U.S. government signed on December 22 to reduce prices for certain drugs and an investment of $2.3 billion in bioproduction across the Atlantic also illustrate the lab's efforts to regain investor confidence. On the analyst side, recent recommendations remain mixed. Berenberg lowered its price target from 110 to 105 euros in mid-December while maintaining a buy opinion, whereas JP Morgan downgraded the stock to neutral with a target at 95 euros. Conversely, Deutsche Bank reiterates its buy recommendation with a target of 110 euros, estimating that the potential upside is around 32% from the current price. These divergent views reflect uncertainties over the group's clinical pipeline, particularly after announced delays on tolebrutinib.
